Leukemia News

Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute and Emilio Ramos, MD, PhD, of University of California, San Francisco, received the ASH-Harold Amos Medical Faculty Development Program Award.

Patients with newly diagnosed cancer were more likely to develop kidney failure than a group of controls without cancer who exhibited similar characteristics in terms of age, sex, eGFR and the presence of diabetes or hypertension.

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.

A lower dose of cyclophosphamide during preconditioning prior to tumor-infiltrating lymphocyte infusion appeared comparably effective but less toxic than a higher dose, according to results published in Journal for ImmunoTherapy of Cancer.

A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer, according to study results published in JCO Oncology Practice.

Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.

Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.

CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.

Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.

The addition of ivosidenib tablets to azacitidine prolonged EFS among patients with previously untreated IDH1-mutated acute myeloid leukemia, according to topline data released by the agent’s manufacturer.